Insiders Double Down on Medical Firm Despite Bad Diagnosis...

Hey Trader, The point of reviewing financials, earnings reports, and other research on a prospective company is to determine if it's worth the investment. If that's the case, why would you still invest in the company within days of receiving bad news about it? Well, four company insiders just did that in the Insider Report's latest pick. This early stage biotech firm has been making key breakthroughs in treating multiple genetic diseases. Unfortunately, they also missed a significant mark with one of their products recently. No, patients didn't experience any crazy side effects, like growing a third foot. But the company did miss it's "primary endpoint" in the development of the new drug. While this revelation is certainly bad news for a medical research company, it's not the end of the world for them. On the heels of this news, four insiders dropped six-figures on company stocks, including a number of VPs and Directors, and the Chief Medical officer. But why? If you want the details of where the smart money is going, and why, check out the free video below! Click here for the doctor's notes on this opportunity. Until next time, Dustin Pass CEO, Market Traders Daily. Market Traders Daily Director of Client Services 888-228-2376 Disclaimer:Futures, forex, stock, and options trading are not appropriate for all traders. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or methodology has ever been developed that can ensure returns or against losses. No representation or implication is being made that using any of these methodologies or systems will generate returns or ensure against losses.

If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription
Global Profit Systems International, 15502 Stoneybrook West Parkway Suite 104-153, Winter Garden, FL 34787, US